Congratulations to the 2024 AACR Fellows #AACR24 , strong showing of chemical biology including PROTAC inventor Craig Crews and Sarafan ChEM-H institute scholar Nathanael Gray!

Congratulations to Craig Crews, elected to the 2024 Class of Fellows of the AACR Academy.
Read more: aacr.org/about-the-aacr…
Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp Department of MCDB

Craig Crews is the awardee of the 2024 IUPAC-Richter Prize (@IUPAC Gedeon Richter)! The acceptance lecture will be held in Rome, Italy (Sept. 1-5, 2024) at the #EFMCISMC24 (efmc-ismc.org). What an addition to an already amazing program!
EFMC DCF-SCI

Congratulations to Craig Crews on receiving the Kimberly Prize from Northwestern Feinberg School of Medicine for pioneering studies of #PROTACs in the lab and their translation to clinical trials! Read more here: news.feinberg.northwestern.edu/2023/12/05/pio…

fedi.video/w/cbQE3NRw76Fa…

Thousands of scientists are cutting back on Twitter, seeding angst and uncertainty nature.com/articles/d4158… I'm @[email protected]

Targeted Protein Degradation gets a nod from the Gabbay Award in Biotechnology and Medicine, a one-of-a-kind award administered by Brandeis University that recognizes practical applications in biomedical sciences - congratulations to Ray Deshaies, and Craig Crews
brandeis.edu/now/2023/july/…

Scientists say they can’t rely on Twitter anymore theverge.com/2023/5/31/2373… via @Verge I can be found on Mastodon @[email protected]

Grateful to see our work highlighted alongside leaders in the field @craigmcrews Ingrid Wertz The Amit Choudhary Lab Stuart Schreiber in the exciting and exploding area of proximity-inducing modalities for drug discovery in Nature Reviews Drug Discovery nature.com/articles/d4157…

A Rookie’s Guide to Using Mastodon by Celine Lai link.medium.com/fh1pB8ph0xb I can be found at @[email protected]

Ever try to drug an oncoprotein driver only to have the tumor lose its dependency on it and become drug resistant? Introducing RIPTACs (Regulated Induced Proximity Targeting Chimeras) in collaboration with Halda Therapeutics.

Craig Crews-founded startup Halda Therapeutics raises $76 million with hopes to create new cancer medicines

endpts.com/protacs-to-rip…

An Oral RIPTAC™ Therapeutic for Prostate Cancer businesswire.com/news/home/2023…

Protein degraders enter the clinic — a new approach to cancer therapy in NatureRevClinOncol
Craig Crews
Keith Hornberger
nature.com/articles/s4157…

In a new Review, Deborah Chirnomas, Keith Hornberger & Craig Crews discuss advances that supported the entry of heterobifunctional protein degraders into clinical studies and describe the first data emerging from these studies: nature.com/articles/s4157… #bcsm #PCSM #hemeonc #caxtx

Calling on my friends and leaders in the field to support and send us your students and postdocs!
Alessio Ciulli Dan Nomura Ivan Đikić Craig Crews michele pagano Joazeiro Lab Rapé Lab Carolyn Bertozzi Michelle Arkin Kylie Walters (she/her) @David_Lab_MSK

Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality pubs.acs.org/doi/10.1021/ja…

Excited to share our Tau PhosTAC paper on J. Am. Chem. Soc. . PhosTAC provides a new modality for neurodegenerative diseases treatment. Many thanks to Craig Crews, and the awesome team Po-Han Chen, Wenxue Li, Todd Douglas , John Yansheng Liu 🎉 #PhosTAC
pubs.acs.org/doi/10.1021/ja…

“The biotech sector is rapidly growing however not all of our communities are benefitting equally in these successes. We started BioLaunch to help those in New Haven who might need a hand in getting into the biotech industry.” Craig Crews, Yale University professor & Arvinas founder

I'm excited to work with ConnCAT and CareerConneCT to start #BioLaunch , a program to help non-college bound New Haven residents get a start in the local Biotech community. The Open House is Monday 2/6 at 7pm. conta.cc/3JpuZD4 Workforce Alliance